|3.||Autoimmune Hemolytic Anemia (Cold Agglutinin Disease)
|4.||B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
|5.||Hairy Cell Leukemia
|1.||Treon, Steven P: 72 articles (08/2015 - 04/2003)|
|2.||Ghobrial, Irene M: 54 articles (09/2015 - 11/2003)|
|3.||Leleu, Xavier: 32 articles (11/2015 - 05/2006)|
|4.||Patterson, Christopher J: 29 articles (07/2014 - 03/2005)|
|5.||Gertz, Morie A: 27 articles (10/2015 - 01/2002)|
|6.||Hunter, Zachary R: 27 articles (10/2014 - 03/2005)|
|7.||Roccaro, Aldo M: 26 articles (02/2015 - 03/2008)|
|8.||Sacco, Antonio: 25 articles (06/2014 - 08/2007)|
|9.||Anderson, Kenneth C: 25 articles (08/2013 - 04/2003)|
|10.||Dimopoulos, Meletios A: 23 articles (11/2015 - 05/2002)|
|1.||rituximab (Mabthera)FDA Link
01/20/2005 - "Rituximab is an important therapeutic for Waldenstrom's macroglobulinemia (WM). "
07/01/2011 - "The incorporation of rituximab into various regimens has improved depth of response in Waldenstrom macroglobulinaemia (WM), though the impact of achieving better responses remains to be determined. "
12/01/1999 - "To assess the preliminary efficacy of rituximab therapy in Waldenstrom's macroglobulinemia (WM), we examined the clinical and laboratory data for all patients with WM treated on IDEC Pharmaceuticals sponsored trials and one patient treated at Walter Reed Army Medical Center. "
08/01/2011 - "Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen."
08/01/2011 - "This study examined the outcome of 248 Waldenstrom macroglobulinaemia (WM) rituximab-naïve patients who responded to a rituximab-containing regimen. "
09/01/2005 - "Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenström's macroglobulinemia."
02/01/1995 - "Fludarabine is an interesting new salvage agent effective against recurrent/resistant Waldenstrom's macroglobulinemia and should be evaluated in further studies in untreated patients with Fludarabine in monochemotherapy or in combination with other active modalities."
09/01/1994 - "Fludarabine is effective in Waldenstrom's macroglobulinemia and is active in other low grade lymphoid malignancies. "
03/01/1994 - "2chlorodeoxyadenosine may be effective in patients with Waldenström macroglobulinemia sensitive to fludarabine. "
04/01/2003 - "We report an update on a prospective observational trial for Waldenstrom's macroglobulinemia (WM) that called for re-registration to treatment with fludarabine (30 mg/m(2)) upon the development of symptomatic or progressive disease. "
|3.||Cyclophosphamide (Cytoxan)FDA LinkGeneric
02/01/2005 - "Cutaneous Waldenstrom's macroglobulinemia with "deck-chair" sign treated with cyclophosphamide."
04/01/1996 - "Mucinous (colloid) carcinoma of urinary bladder following long-term cyclophosphamide therapy for Waldenstrom's macroglobulinemia."
12/01/1991 - "We report a case of upper urothelial tumor in a patient who had previously received prolonged cyclophosphamide therapy for Waldeström's macroglobulinemia. "
01/01/1968 - "[Macrocellular reticulum cell sarcoma as late clinical stage of an endoxan-treated Waldenström's macroglobulinemia]."
01/01/2011 - "Cyclophosphamide (CP) is widely used in the treatment of tumors and B-cell malignant disease, such as lymphoma, myeloma, chronic lymphocytic leukemia, and Waldenstrom's macroglobulinemia. "
|4.||Dexamethasone (Maxidex)FDA LinkGeneric
02/01/1988 - "We conclude that high dose dexamethasone may offer significant benefits in the treatment of Waldenstrom's macroglobulinemia."
01/01/2013 - "To evaluate the efficacy of one intravitreal injection of dexamethasone (Ozurdex(®); Allergan, Inc., Irvine, Calif., USA) in serous macular detachment (SMD) of one eye, associated with bilateral central retinal vein occlusion (CRVO) in a patient affected by Waldenström's macroglobulinemia (WM). "
09/10/2015 - "Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study."
11/07/2013 - "Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)."
06/01/2015 - "Cyclophosphamide, bortezomib, and dexamethasone combination in waldenstrom macroglobulinemia."
07/01/2000 - "The aim of the study was to evaluate the results of treatment of Waldenström's Macroglobulinemia with 2-chlorodeoxyadenosine. "
02/01/2006 - "Transformation and progression of Waldenström's macroglobulinemia following cladribine therapy in two cases: natural evolution or iatrogenic causation?"
04/01/2003 - "2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia."
07/01/2000 - "2-Chlorodeoxyadenosine treatment of Waldenström's macroglobulinemia--the analysis of own experience and the review of literature."
07/01/1999 - "Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenström's macroglobulinemia."
|6.||bortezomib (Velcade)FDA Link
04/01/2009 - "This report provides an update on biological studies and clinical efforts to develop bortezomib as a new treatment of Waldenstrom's macroglobulinemia."
06/01/2007 - "Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248."
04/20/2007 - "Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group."
08/01/2015 - "Successful treatment of refractory cold hemagglutinemia in MYD88 L265P mutation-negative Waldenström's macroglobulinemia with bortezomib."
04/01/2010 - "These encouraging data have led to the inclusion of bortezomib as a salvage treatment option in the recently updated Fourth International Workshop on Waldenström's Macroglobulinemia treatment recommendations."
|7.||Chlorambucil (Leukeran)FDA Link
09/15/1987 - "The authors present a case of Waldenström's macroglobulinemia in which the patient developed cutaneous lesions while his systemic disease seemed to be under control with chlorambucil therapy. "
06/01/1983 - "Pasteurella multocida was grown from subcutaneous aspirate and blood cultures of a single patient; he was immunocompromised by Waldenström's macroglobulinemia and chlorambucil therapy. "
12/01/1974 - "[A case of Sjögren's syndrome associated with macroglobulinemia which responded excellently to chlorambucil]."
04/29/1972 - "Development of acute leukaemia in Waldenstrom's macroglobulinaemia after prolonged treatment with chlorambucil."
08/09/1971 - "[Leukeran in treatment of macroglobulinemia]."
|8.||Prednisone (Sone)FDA LinkGeneric
05/01/1959 - "[Case of Waldenström's macroglobulinemia treated with ATCH & prednisone]."
11/01/1983 - "A patient with polyneuropathy due to Waldenström's macroglobulinemia (WM) was treated successfully with chlorambucil and prednisone. "
12/01/1992 - "Philadelphia chromosome-positive chronic myeloid leukaemia (CML) developed three years after the diagnosis of Waldenström macroglobulinemia (WM) in a patient who had received chlorambucil and prednisone during this time. "
11/30/1984 - "We report one case of B-lymphocyte CLL with macroglobulinemia, treated with melphalan and prednisone, in which DHL developed and the hematologic and histologic signs of CLL and of paraproteinemia remissed. "
06/01/2006 - "We report a new case of prosthetic knee arthritis due to Listeria in a woman with seropositive rheumatoid arthritis and Waldenström s macroglobulinemia receiving prednisone and methotrexate. "
|9.||Pentostatin (Nipent)FDA LinkGeneric
04/01/1986 - "Response of Waldenstrom's macroglobulinemia to pentostatin (2'-deoxycoformycin)."
01/01/2015 - "Pentostatin, cyclophosphamide and rituximab is a safe and effective treatment in patients with Waldenström's macroglobulinemia."
09/01/2005 - "Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma."
09/01/2005 - "We conducted a phase II trial with the combination regimen of PC-R (pentostatin/cyclophosphamide with or without rituximab) in 14 patients with Waldenstrom's macroglobulinemia (WM) and 3 patients with lymphoplasmacytic lymphoma (LL) without monoclonal serum immunoglobulin M (IgM), followed by a maintenance regimen with rituximab (375 mg/m2 every 3 months) for patients exhibiting a complete response (CR) or a partial response (PR) after 4-6 cycles. "
|10.||Prednisolone (Predate)FDA LinkGeneric
09/01/2001 - "He was placed on prednisolone, which resulted in improvement in his myasthenic symptoms, but the prolongation of APTT and macroglobulinemia remained. "
12/20/1958 - "Effect of prednisolone on anaemia associated with macroglobulinemia."
01/01/2012 - "A 60-year-old man with Waldenström's macroglobulinemia (WM) was admitted to our hospital for evaluation of rapid progressive renal deterioration despite 3 cycles of oral melphalan and prednisolone (MP) therapy. "
01/01/2000 - "Although the exact mechanism for pathophysiology of acute renal failure remains unknown, treatment with prednisolone and cyclophosphamide could induce a rapid recovery from acute renal failure accompanied by Waldenström's macroglobulinemia and type I cryoglobulinemia."
07/01/2003 - "After treatment with prednisolone and melphalan, proteinuria disappeared, but macroglobulinemia and cryoglobulinemia were not improved."
|1.||Drug Therapy (Chemotherapy)
07/01/2015 - "He had previously developed primary macroglobulinemia, which had been completely cured by chemotherapy. "
03/01/1995 - "We describe a case of dry eye associated with Waldenström's macroglobulinemia that responded poorly to substitutive topical treatment but improved spectacularly in response to systemic chemotherapy. "
01/01/2014 - "Clinical factors associated with response or survival after chemotherapy in patients with Waldenström macroglobulinemia in Korea."
01/01/2013 - "Chemotherapy consistent of drugs active against both the lymphoid and plasma cell components of the disease is the proposed therapy for Waldenstrom's macroglobulinaemia in those patients amenable to receive chemotherapy and can make a difference in the survival."
01/01/2008 - "Effect of chemotherapy schedule on response in Waldenström's macroglobulinemia in a dog."
04/01/2013 - "Despite the absence of randomized trials, plasmapheresis has consistently demonstrated efficacy in treatment of Waldenström's macroglobulinemia (WM) patients with hyperviscosity syndrome (HVS). "
04/01/1962 - "Metabolic balance study of plasmapheresis in a case of Waldenstrom's macroglobulinemia."
04/01/2013 - "Role of plasmapheresis in Waldenström's macroglobulinemia."
03/01/2009 - "Ophthalmologic techniques to assess the severity of hyperviscosity syndrome and the effect of plasmapheresis in patients with Waldenström's macroglobulinemia."
07/01/2005 - "Identification of this rare variant of the classic angiographically silent macula known to occur with Waldenström's macroglobulinemia can aid the clinician in determining a patient's potential response to plasmapheresis and their final visual prognosis."
|3.||Stem Cell Transplantation
05/01/2007 - "Autologous stem cell transplantation as part of first-line treatment of Waldenström's macroglobulinemia."
02/01/2011 - "Autologous stem cell transplantation as a care option in Waldenström's macroglobulinemia."
06/01/2010 - "Allogeneic stem cell transplantation yields a high rate of complete remissions and is potentially curative in poor-risk Waldenström's macroglobulinemia."
06/01/2010 - "We examined the long-term outcome of allogeneic stem cell transplantation in Waldenström's macroglobulinemia by studying the records of 24 patients reported in the SFGM-TC database and one transplanted in the bone marrow unit in Hamburg. "
05/01/2010 - "The role of autologous stem-cell transplantation (ASCT) in Waldenström macroglobulinemia (WM) is not defined. "
04/01/1995 - "Durable complete remission of macroglobulinemia after splenectomy: a report of two cases and review of the literature."
04/01/1995 - "A review of the literature revealed other cases of remission of macroglobulinemia attributable to splenectomy alone. "
04/01/1995 - "The other patient remained free of detectable macroglobulinemia for 13 years after splenectomy. "
01/01/2002 - "Advanced waldenström's macroglobulinemia: a case of possible cure after systemic chemotherapy, splenic radiation and splenectomy."
07/01/1997 - "Durable remission after splenectomy for Waldenström's macroglobulinemia with massive splenomegaly in leukemic phase."
08/01/2006 - "8 patients were successfully treated using the conventional packing method, 2 patients were treated using electrocauterization, and 1 patient with macroglobulinemia was treated using plasma exchange therapy. "
01/01/1986 - "[Alleviation of ocular complications of the hyperviscosity syndrome in Waldenström's macroglobulinemia using plasma exchange]."
07/23/1977 - "Two patients with Waldenström's macroglobulinemia (WM), which had become resistant to cytotoxic drugs, were treated for features of the hyperviscosity syndrome by repeated plasma exchange with the continuous-flow blood-cell separator over periods of 36 and 28 months, respectively. "
07/23/1977 - "Plasma exchange in the long-term management of Waldenström's macroglobulinemia."
01/01/1991 - "Analyses of erythrocyte aggregation have been carried out in 15 patients with multiple myeloma or Waldenström's macroglobulinemia before and after plasma exchange. "